• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of Gemcitabine and Cisplatin chemotherapy in combination with Sunitinib as first-line treatment for patients with advanced urothelial carcinoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Geldart, T
    Chester, J
    Casbard, A
    Crabb, S
    Elliott, Tony
    Protheroe, A
    Huddart, R
    Mead, G
    Barber, J
    Jones, R
    Smith, J
    Cowles, R
    Evans, J
    Griffiths, G
    Show allShow less
    Affiliation
    Royal Bournemouth Hospital, Bournemouth, UK
    Issue Date
    2014-11-20
    
    Metadata
    Show full item record
    Abstract
    Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment for advanced urothelial carcinoma. We performed an open-label, single-arm, non-randomised, phase 2 trial evaluating the addition of sunitinib to standard GC chemotherapy (SGC regimen). Overall, 63 treatment-naïve participants were recruited and received up to six 21-d cycles of cisplatin 70mg/m(2) (intravenously [IV], day 1) and gemcitabine 1000mg/m(2) (IV, days 1 and 8) combined with sunitinib 37.5mg (orally, days 2-15). Following review of toxicity after the first six patients, the sunitinib dose was reduced to 25mg for all patients. Overall response rate was 64%, with response noted in 37 of 58 patients. At 6 mo, 30 of 58 assessable patients (52%; 90% confidence interval [CI], 40-63%) were progression free. Median overall survival was 12 mo (95% CI, 9-15) and was heavily influenced by Bajorin prognostic group. Grade 3-4 toxicities were predominantly haematologic and limited the deliverability of the triple SGC regimen. The trial did not meet its prespecified primary end point of >60% patients progression free at 6 mo. Cumulative myelosuppression led to treatment delays of gemcitabine and cisplatin and dose reduction and/or withdrawal of sunitinib in the majority of cases. The triple-drug combination was not well tolerated. Phase 3 evaluation of the triple SGC regimen in advanced transitional cell carcinoma is not recommended.
    Citation
    SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of Gemcitabine and Cisplatin chemotherapy in combination with Sunitinib as first-line treatment for patients with advanced urothelial carcinoma. 2014: Eur Urol
    Journal
    European Urology
    URI
    http://hdl.handle.net/10541/338689
    DOI
    10.1016/j.eururo.2014.11.003
    PubMed ID
    25465968
    Type
    Article
    ISSN
    1873-7560
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.eururo.2014.11.003
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma.
    • Authors: Chang SS
    • Issue date: 2015 Dec
    • Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
    • Authors: Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M, Vogelzang NJ, Kocs D, McKenney SA, Melnyk AM Jr, Hutson TE, Rauch M, Wang Y, Asmar L, Sonpavde G
    • Issue date: 2013 Jun
    • Heir to the throne or young pretender: can targeted therapy added to gemcitabine-cisplatin doublet therapy improve outcomes for advanced urothelial cancer?
    • Authors: Birtle A
    • Issue date: 2015 Apr
    • Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    • Authors: Urakami S, Fujii Y, Yamamoto S, Yuasa T, Kitsukawa S, Sakura M, Yano A, Saito K, Masuda H, Yonese J, Fukui I
    • Issue date: 2014 Jan
    • Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
    • Authors: Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX Jr, Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E
    • Issue date: 2020 Apr 18
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.